Clotrimazole/diclofenac - ProFem
Alternative Names: Candiplus; Clotrimazole/diclofenac sodium; ProF 001Latest Information Update: 25 Jul 2022
At a glance
- Originator ProFem
- Class Antifungals; Antipyretics; Antirheumatics; Imidazoles; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action 14-alpha demethylase inhibitors; Cell membrane modulators; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Candidiasis
Highest Development Phases
- Phase II/III Vulvovaginal candidiasis
Most Recent Events
- 25 Jul 2022 Clotrimazole/diclofenac is still in phase-II/III trials for Vulvovaginal candidiasis (Recurrent) in Austria, Slovakia and Poland (Vaginal) (NCT04734405)(EudraCT2019-000925-27)
- 10 Jun 2019 Profem initiates enrolment in a phase II/III trial in Vulvovaginal candidiasis (Recurrent) in Austria (Vaginal) (NCT04734405)
- 06 Jun 2019 Phase-II/III clinical trials in Vulvovaginal candidiasis (Recurrent) in Slovakia and Poland (Vaginal) (NCT04734405)